for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TAISHO PHARMACEUTICAL HOLDINGS Co Ltd

4581.T

Latest Trade

8,010.00JPY

Change

100.00(+1.26%)

Volume

210,900

Today's Range

7,920.00

 - 

8,070.00

52 Week Range

7,170.00

 - 

14,130.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
7,910.00
Open
7,990.00
Volume
210,900
3M AVG Volume
2.62
Today's High
8,070.00
Today's Low
7,920.00
52 Week High
14,130.00
52 Week Low
7,170.00
Shares Out (MIL)
79.81
Market Cap (MIL)
673,454.60
Forward P/E
21.20
Dividend (Yield %)
1.39

Next Event

Dividend For 4581.T - 50.0000 JPY

Latest Developments

More

Taisho Pharmaceutical Completes Procedures For Acquisition Of UPSA SAS

Taisho Pharmaceutical Holdings: To Buy UPSA For $1.6 Billion From Bristol-Myers

Taisho Is Said To Near $1.6 Bln Deal For Bristol-Myers's Upsa Unit - Bloomberg

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About TAISHO PHARMACEUTICAL HOLDINGS Co Ltd

TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. is a holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Self-Medication segment is engaged in the research, development, manufacture and sale of general pharmaceuticals, general foods, medical supplies and others. The Medical segment is engaged in the research, development, manufacture and sale of ethical drugs. The Company, through its subsidiaries and associated companies, is also engaged in the provision of logistics services, the leasing, management and operation of real estate, as well as the manufacture and sale of medical alcohols.

Industry

Major Drugs

Contact Info

3-24-1, Takada

+81.3.39852020

http://www.taisho-holdings.co.jp

Executive Leadership

Akira Uehara

President, Chairman of Subsidiary, Representative Director

Kenichi Fujita

President of Subsidiary, Director

Ken Uehara

Chairman of Subsidiary, Director

Shigeru Uehara

Vice President, President of Subsidiary, Director

Kazuya Kameo

Executive Director

Key Stats

3.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.3K

2018

0.3K

2019

0.3K

2020(E)

0.3K
EPS (JPY)

2017

360.180

2018

396.540

2019

608.796

2020(E)

373.169
Price To Earnings (TTM)
13.76
Price To Sales (TTM)
2.59
Price To Book (MRQ)
0.89
Price To Cash Flow (TTM)
11.56
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
6.38
Return on Equity (TTM)
5.81

Latest News

Bristol-Myers gets $1.6 billion offer for French consumer health unit

Bristol-Myers Squibb Co <BMY.N> received an offer from Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd <4581.T> to buy the company's French over-the-counter drugs business UPSA for $1.6 billion, the companies said on Wednesday.

Bristol-Myers gets $1.6 bln offer for French consumer health unit

Bristol-Myers Squibb Co received an offer from Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd to buy the company's French over-the-counter drugs business UPSA for $1.6 billion, the companies said on Wednesday.

Taisho said to near $1.6 billion deal for Bristol-Myers's UPSA - Bloomberg

Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd <4581.T> is said to be close to a $1.6 billion (1.3-billion pound) deal for Bristol-Myers Squibb Co's <BMY.N> French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar...

Taisho said to near $1.6 billion deal for Bristol-Myers's UPSA: Bloomberg

Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd <4581.T> is said to be close to a $1.6 billion deal for Bristol-Myers Squibb Co's <BMY.N> French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up